Akoya Biosciences(US:AKYA) Newsfilter·2025-04-23 12:00Core Insights - Akoya Biosciences has announced a collaboration with the Singapore Translational Cancer Consortium (STCC) for the SUPER study, aimed at identifying biomarkers for immune checkpoint inhibitor responses [1][2] - The study will focus on a unique cohort of 200 patients, including 100 exceptional responders and 100 hyperprogressors, to understand the biological determinants of treatment outcomes [2][4] - The collaboration will utilize Akoya's IO60 panel for spatial proteomic analysis, enhancing biomarker-driven cancer treatment [5][7] Study Objectives - Identify and validate the assay combination and biomarker profile that best predicts response or refractoriness to PD1/PDL1 inhibition [8] - Develop a combinatorial assay kit/model for predicting PD1/PDL1 treatment response for clinical applications [8] - Establish a national biomarker discovery program for extreme responders to cancer treatment [8] Collaboration Significance - The SUPER study represents a national effort to redefine immunotherapy strategies in Singapore, integrating public healthcare and research institutions [4][7] - The partnership aims to bridge spatial proteomics with clinical insights, potentially shaping the future of precision oncology [7] - Akoya's IO60 panel will provide critical insights into the tumor microenvironment, which could lead to more effective cancer treatments and healthcare cost optimization [5][6]